Watch for the final IPO pricing and the extent to which the $60.0 million in non-binding indications of interest from ARK and Duquesne convert into actual purchases, which will affect the public float. Monitor upcoming clinical data readouts for IAM1363 and the IND filings for IAM217 and IAM-C1, as these are the primary value drivers for this pre-revenue company.
Executive Summary
Iambic Therapeutics, an AI-driven clinical-stage biopharmaceutical company, filed Amendment No. 1 to its S-1 for an IPO of 9,375,000 shares of common stock at an expected price of $15.00-$17.00 per share, seeking to list on Nasdaq under the ticker 'IAM'. The company, which integrates its 'molecular superintelligence' AI platform with automated experimentation to discover small-molecule oncology drugs, has no approved products and reported a net loss of $50.1 million for the six months ended June 30, 2026, on collaboration revenue of $12.8 million. Net proceeds are estimated at $135.0 million (or $155.9 million with full underwriter option exercise), primarily to fund clinical development of its lead candidate IAM1363 and preclinical programs IAM217 and IAM-C1, extending its cash runway into or through Q4 2028.
Key Financial Metrics
Key Facts
- IPO of 9,375,000 shares of common stock at an expected price of $15.00-$17.00 per share; underwriters have a 30-day option to purchase up to 1,406,250 additional shares.
- Company seeking to list on The Nasdaq Global Select Market under the symbol 'IAM'.
- Net proceeds estimated at approximately $135.0 million (or $155.9 million if underwriters' option is exercised in full), based on an assumed IPO price of $16.00 per share.
- ARK Investment Management LLC and Duquesne Family Office LLC have expressed non-binding indications of interest to purchase up to an aggregate of $60.0 million in shares.
- Collaboration revenue was $12.8 million for the six months ended June 30, 2026, up 225% from $3.9 million in the prior-year period.
- Net loss was $50.1 million for the six months ended June 30, 2026, compared to $33.2 million in the prior-year period; net loss was $77.3 million for the year ended December 31, 2025.
- As of June 30, 2026, the company had $207.9 million in cash and cash equivalents and an accumulated deficit of $245.3 million.
- Existing cash and cash equivalents, together with estimated net proceeds from the offering, are expected to fund operations into or through the fourth quarter of 2028.
- Lead candidate IAM1363 is in an ongoing Phase 1/1b clinical trial for HER2-altered solid tumors; IAM217 and IAM-C1 are in preclinical development.
- Company has raised approximately $461.8 million in capital since inception through September 18, 2026.
- Pro forma as adjusted net tangible book value per share immediately after the offering is estimated at $7.65, resulting in immediate dilution of $8.35 per share to new investors at the assumed IPO price.
- Insiders will beneficially own approximately 28.9% of outstanding common stock after the offering.
Financial Impact
IPO expected to raise approximately $135.0 million in net proceeds (or $155.9 million with full option exercise) at the assumed $16.00 midpoint price. Company reported a net loss of $50.1 million on $12.8 million in collaboration revenue for H1 2026, with an accumulated deficit of $245.3 million as of June 30, 2026.
Risk Factors
- No products approved for commercial sale and no revenue from product sales; the company has a history of significant losses and negative cash flows.
- The company's AI-driven drug discovery approach is novel and unproven, and may not lead to successful, commercially viable drug products.
- Lead candidate IAM1363 is in early-stage Phase 1/1b trials, and other programs are preclinical; drug development is lengthy, expensive, and uncertain.
- Substantial additional capital will be required to complete development and commercialization, which may not be available on acceptable terms.
- Revenue is concentrated among a small number of collaboration partners, and the loss of any one could materially impact results.
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001193125-26-417416 |
| Document: iam-ex10_3.htm | 0001193125-26-417416 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | Insider Buy | $16.01 $15.80 | ▼ −1.31% | ▼ −1.84% | $14.26 (−10.93%) |
Oct 16, 2026 10d ago | 8-K | $16.34 $16.01 | ▼ −2.02% | ▼ −2.35% | $14.26 (−12.73%) |
Oct 15, 2026 11d ago | 424B4 | $23.81 $16.34 | ▼ −31.37% | ▼ −31.80% | $14.26 (−40.11%) |
Oct 15, 2026 11d ago | EFFECT | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.26 (−24.59%) |
Oct 14, 2026 12d ago | 3 | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.26 (−24.59%) |
Oct 14, 2026 12d ago | 3 | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.26 (−24.59%) |
Oct 14, 2026 12d ago | 3 | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.26 (−24.59%) |
Oct 14, 2026 12d ago | 3 | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.26 (−24.59%) |
Oct 14, 2026 12d ago | 3 | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.26 (−24.59%) |
Oct 14, 2026 12d ago | 3 | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.26 (−24.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers